These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 26918260)

  • 1. Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor.
    Deng R; Bumbaca D; Pastuskovas CV; Boswell CA; West D; Cowan KJ; Chiu H; McBride J; Johnson C; Xin Y; Koeppen H; Leabman M; Iyer S
    MAbs; 2016; 8(3):593-603. PubMed ID: 26918260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors.
    Chatterjee S; Lesniak WG; Gabrielson M; Lisok A; Wharram B; Sysa-Shah P; Azad BB; Pomper MG; Nimmagadda S
    Oncotarget; 2016 Mar; 7(9):10215-27. PubMed ID: 26848870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 inhibition with MPDL3280A for solid tumors.
    Cha E; Wallin J; Kowanetz M
    Semin Oncol; 2015 Jun; 42(3):484-7. PubMed ID: 25965367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody.
    Stewart R; Morrow M; Hammond SA; Mulgrew K; Marcus D; Poon E; Watkins A; Mullins S; Chodorge M; Andrews J; Bannister D; Dick E; Crawford N; Parmentier J; Alimzhanov M; Babcook JS; Foltz IN; Buchanan A; Bedian V; Wilkinson RW; McCourt M
    Cancer Immunol Res; 2015 Sep; 3(9):1052-62. PubMed ID: 25943534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity.
    Luan Y; Chai D; Peng J; Ma S; Wang M; Ma H; Li X; Fu S; Pan X; Wang X; Qin S; Xu T
    Int Immunopharmacol; 2016 Feb; 31():248-56. PubMed ID: 26773772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1/PD-L1 inhibitors.
    Sunshine J; Taube JM
    Curr Opin Pharmacol; 2015 Aug; 23():32-8. PubMed ID: 26047524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies.
    Heskamp S; Hobo W; Molkenboer-Kuenen JD; Olive D; Oyen WJ; Dolstra H; Boerman OC
    Cancer Res; 2015 Jul; 75(14):2928-36. PubMed ID: 25977331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Treatment of Melanoma: Combined Parasite-Derived Peptide GK-1 and Anti-Programmed Death Ligand 1 Therapy.
    Vera-Aguilera J; Perez-Torres A; Beltran D; Villanueva-Ramos C; Wachtel M; Moreno-Aguilera E; Vera-Aguilera C; Ventolini G; Martínez-Zaguilán R; Sennoune SR
    Cancer Biother Radiopharm; 2017 Mar; 32(2):49-56. PubMed ID: 28301259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 Detection in Tumors Using [(64)Cu]Atezolizumab with PET.
    Lesniak WG; Chatterjee S; Gabrielson M; Lisok A; Wharram B; Pomper MG; Nimmagadda S
    Bioconjug Chem; 2016 Sep; 27(9):2103-10. PubMed ID: 27458027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical pharmacokinetic characterization of an adipose tissue-targeting monoclonal antibody in obese and non-obese animals.
    Rajan S; Mandikian D; Baruch A; Gelzleichter TR; Stevens D; Sonoda J; Cowan K; Boswell CA; Stefanich E
    MAbs; 2017; 9(8):1379-1388. PubMed ID: 28895785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation, characterization and preclinical studies of a human anti-L1CAM monoclonal antibody that cross-reacts with rodent L1CAM.
    Cho S; Park I; Kim H; Jeong MS; Lim M; Lee ES; Kim JH; Kim S; Hong HJ
    MAbs; 2016; 8(2):414-25. PubMed ID: 26785809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer.
    Bagley SJ; Bauml JM; Langer CJ
    Clin Adv Hematol Oncol; 2015 Oct; 13(10):676-83. PubMed ID: 27058572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1 Antibody Pharmacokinetics and Tumor Targeting in Mouse Models for Infectious Diseases.
    Sandker GGW; Adema G; Molkenboer-Kuenen J; Wierstra P; Bussink J; Heskamp S; Aarntzen EHJG
    Front Immunol; 2022; 13():837370. PubMed ID: 35359962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptide-based PET quantifies target engagement of PD-L1 therapeutics.
    Kumar D; Lisok A; Dahmane E; McCoy M; Shelake S; Chatterjee S; Allaj V; Sysa-Shah P; Wharram B; Lesniak WG; Tully E; Gabrielson E; Jaffee EM; Poirier JT; Rudin CM; Gobburu JV; Pomper MG; Nimmagadda S
    J Clin Invest; 2019 Feb; 129(2):616-630. PubMed ID: 30457978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis.
    Black M; Barsoum IB; Truesdell P; Cotechini T; Macdonald-Goodfellow SK; Petroff M; Siemens DR; Koti M; Craig AW; Graham CH
    Oncotarget; 2016 Mar; 7(9):10557-67. PubMed ID: 26859684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.
    Carbognin L; Pilotto S; Milella M; Vaccaro V; Brunelli M; Caliò A; Cuppone F; Sperduti I; Giannarelli D; Chilosi M; Bronte V; Scarpa A; Bria E; Tortora G
    PLoS One; 2015; 10(6):e0130142. PubMed ID: 26086854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.
    Powles T; Eder JP; Fine GD; Braiteh FS; Loriot Y; Cruz C; Bellmunt J; Burris HA; Petrylak DP; Teng SL; Shen X; Boyd Z; Hegde PS; Chen DS; Vogelzang NJ
    Nature; 2014 Nov; 515(7528):558-62. PubMed ID: 25428503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity.
    Hamilton G; Rath B
    Expert Opin Biol Ther; 2017 Apr; 17(4):515-523. PubMed ID: 28274143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model.
    Luheshi NM; Coates-Ulrichsen J; Harper J; Mullins S; Sulikowski MG; Martin P; Brown L; Lewis A; Davies G; Morrow M; Wilkinson RW
    Oncotarget; 2016 Apr; 7(14):18508-20. PubMed ID: 26918344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody.
    Fu J; Wang F; Dong LH; Zhang J; Deng CL; Wang XL; Xie XY; Zhang J; Deng RX; Zhang LB; Wu H; Feng H; Chen B; Song HF
    Acta Pharmacol Sin; 2017 May; 38(5):710-718. PubMed ID: 28317872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.